| Literature DB >> 8248285 |
Abstract
The role of atrial natriuretic peptide (ANP) and potential defects of ANP in liver disease are reviewed. Patients with cirrhosis of the liver show no decrease of ANP plasma concentrations nor changes in the pattern of ANP immunoreactivity nor changes of splanchnic ANP clearance. The renal effects of exogenously administered as well as endogenously released ANP are blunted in cirrhosis, in particular in patients with ascites. This seems due to increased activity of sodium-retaining hormonal systems and changes of the renal ANP receptor status. Pharmacological inhibition of ANP-degradation or clearance may yield therapeutic potential.Entities:
Mesh：
Substances：
Year: 1993 PMID： 8248285 DOI： 10.1016/0163-7258(93)90028-c
Source DB: PubMed Journal: Pharmacol Ther ISSN： 0163-7258 Impact factor: 12.310